Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Live-attenuated varicella vaccine.

A A Gershon1

  • 1Department of Pediatrics, Columbia University College of Physicians & Surgeons, New York, New York, USA. aag1@columbia.edu

Infectious Disease Clinics of North America
|April 17, 2001
PubMed
Summary

The live attenuated varicella vaccine is safe and highly effective, offering near-complete protection against severe chickenpox. Widespread use is anticipated to significantly impact varicella and zoster epidemiology globally.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay.

Epidemiology and infection·2016
Same author

Diagnostic virology.

Pediatric clinics of North America·2015
Same author

Comparative study of the standard fluorescent antibody to membrane antigen (FAMA) assay and a flow cytometry-adapted FAMA assay to assess immunity to varicella-zoster virus.

Clinical and vaccine immunology : CVI·2011
Same author

Population diversity in batches of the varicella Oka vaccine.

Vaccine·2011
Same author

Evaluation of the time resolved fluorescence immunoassay (TRFIA) for the detection of varicella zoster virus (VZV) antibodies following vaccination of healthcare workers.

Journal of virological methods·2011
Same author

Vaccination to prevent zoster in the elderly.

Epidemiology and infection·2007

Area of Science:

  • Virology
  • Immunology
  • Public Health

Background:

  • Varicella (chickenpox) is a common infectious disease caused by the varicella-zoster virus.
  • The development of a live attenuated vaccine has been a significant advancement in infectious disease control.
  • Global efforts aim to reduce the burden of varicella and its complications.

Purpose of the Study:

  • To review the historical development and global trajectory of the live attenuated varicella vaccine.
  • To assess the safety and immunogenicity profile of the varicella vaccine.
  • To project the impact of widespread varicella vaccination on disease epidemiology.

Main Methods:

  • Literature review of historical data on varicella vaccine development.
  • Analysis of safety data from large-scale immunization programs.
  • Evaluation of immunogenicity and efficacy studies.
  • Epidemiological modeling to predict disease impact.

Main Results:

  • The varicella vaccine originated in Japan and has achieved widespread global adoption.
  • Extensive safety data show an excellent profile, with millions immunized without significant adverse events.
  • The vaccine is highly immunogenic, providing close to 100% protection against severe varicella and 90% against illness.

Conclusions:

  • The live attenuated varicella vaccine is a safe and highly effective public health intervention.
  • High vaccine uptake is expected to substantially alter the epidemiology of varicella and zoster.
  • The vaccine represents a major achievement in the control of viral exanthems.

Related Experiment Videos